Display options
Cite
Ballabio E, Milne TA. Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Mol Cell Oncol. 2014;1(2):e955330doi: 10.1080/23723548.2014.955330.
Ballabio, E., & Milne, T. A. (2014). Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Molecular & cellular oncology, 1(2), e955330. https://doi.org/10.1080/23723548.2014.955330
Ballabio, Erica, and Milne, Thomas A. "Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins." Molecular & cellular oncology vol. 1,2 (2014): e955330. doi: https://doi.org/10.1080/23723548.2014.955330
Ballabio E, Milne TA. Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Mol Cell Oncol. 2014 Oct 29;1(2):e955330. doi: 10.1080/23723548.2014.955330. eCollection 2014. PMID: 27308325; PMCID: PMC4905190.
Copy Download .nbib Format: NLM
Share it on

Mol Cell Oncol. 2014 Oct 29;1(2):e955330. doi: 10.1080/23723548.2014.955330. eCollection 2014.

Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins.

Molecular & cellular oncology

Erica Ballabio, Thomas A Milne

Affiliations

  1. MRC Molecular Hematology Unit; Weatherall Institute of Molecular Medicine; University of Oxford ; Oxford, UK.

PMID: 27308325 PMCID: PMC4905190 DOI: 10.1080/23723548.2014.955330

Abstract

Although there has been great progress in the treatment of human cancers, especially leukemias, many remain resistant to treatment. A major current focus is the development of so-called epigenetic drugs. Epigenetic states are stable enough to persist through multiple cell divisions, but by their very nature are reversible and thus are amenable to therapeutic manipulation. Exciting work in this area has produced a new breed of highly specific small molecules designed to inhibit epigenetic proteins, some of which have entered clinical trials. The current and future development of epigenetic drugs is greatly aided by highly detailed information about normal and aberrant epigenetic changes at the molecular level. In this review we focus on a class of aggressive acute leukemias caused by mutations in the Mixed Lineage Leukemia (MLL) gene. We provide an overview of how detailed molecular analysis of MLL leukemias has provided several early-stage epigenetic drugs and propose that further study of MLL leukemogenesis may continue to provide molecular details that potentially have a wider range of applications in human cancers.

Keywords: MLL; acetylation; chromatin modifications; epigenetic; fusion proteins; histone; leukemia; methylation; small molecule inhibitors; therapy; transcription elongation

References

  1. Genetics. 1999 May;152(1):319-44 - PubMed
  2. Mol Cell Biol. 2000 Jan;20(1):312-8 - PubMed
  3. Mol Cell Biol. 2001 Apr;21(7):2249-58 - PubMed
  4. Mol Cell Biol. 2001 May;21(10):3589-97 - PubMed
  5. Nucleic Acids Res. 2002 Feb 15;30(4):958-65 - PubMed
  6. Mol Cell. 2002 Nov;10(5):1107-17 - PubMed
  7. Mol Cell. 2002 Nov;10(5):1119-28 - PubMed
  8. Mol Cell Biol. 2003 Jan;23(1):186-94 - PubMed
  9. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8342-7 - PubMed
  10. Cancer Cell. 2003 Aug;4(2):99-110 - PubMed
  11. Cell. 1992 Nov 13;71(4):691-700 - PubMed
  12. Cell. 1992 Nov 13;71(4):701-8 - PubMed
  13. Cancer Cell. 2003 Sep;4(3):197-207 - PubMed
  14. Mol Cell Biol. 2003 Nov;23(21):7611-27 - PubMed
  15. Cell. 2003 Oct 31;115(3):293-303 - PubMed
  16. Blood. 2004 May 1;103(9):3544-6 - PubMed
  17. Mol Cell Biol. 2004 Jul;24(13):5639-49 - PubMed
  18. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54 - PubMed
  19. Cell. 2005 Apr 22;121(2):167-78 - PubMed
  20. Cell. 2005 Jun 17;121(6):873-85 - PubMed
  21. Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14765-70 - PubMed
  22. Cell. 2005 Oct 21;123(2):207-18 - PubMed
  23. Cancer Res. 2005 Dec 15;65(24):11367-74 - PubMed
  24. Cancer. 2006 Feb 15;106(4):950-6 - PubMed
  25. Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6629-34 - PubMed
  26. Nat Struct Mol Biol. 2006 Aug;13(8):713-9 - PubMed
  27. Mol Cell. 2007 Jan 12;25(1):15-30 - PubMed
  28. Leukemia. 2007 Jun;21(6):1232-8 - PubMed
  29. Mol Cell. 2007 Jul 6;27(1):107-19 - PubMed
  30. Lancet. 2007 Jul 21;370(9583):240-250 - PubMed
  31. Blood. 2007 Dec 15;110(13):4445-54 - PubMed
  32. Cell Stem Cell. 2007 Sep 13;1(3):324-37 - PubMed
  33. Cell Stem Cell. 2007 Sep 13;1(3):338-45 - PubMed
  34. Proc Natl Acad Sci U S A. 2008 May 27;105(21):7517-22 - PubMed
  35. Cancer Cell. 2008 Jul 8;14(1):36-46 - PubMed
  36. Nature. 2009 Mar 26;458(7237):529-33 - PubMed
  37. Blood. 2009 Sep 17;114(12):2489-96 - PubMed
  38. J Biol Chem. 2009 Sep 4;284(36):24242-56 - PubMed
  39. Mol Cell. 2009 Dec 25;36(6):970-83 - PubMed
  40. Cancer Cell. 2010 Feb 17;17(2):198-212 - PubMed
  41. Mol Cell. 2010 Feb 12;37(3):429-37 - PubMed
  42. Cancer Cell. 2010 Feb 17;17(2):148-59 - PubMed
  43. Cell. 2010 Feb 19;140(4):491-503 - PubMed
  44. Blood. 2010 Apr 29;115(17):3570-9 - PubMed
  45. Science. 2010 Mar 26;327(5973):1650-3 - PubMed
  46. Blood. 2010 Jul 22;116(3):354-65 - PubMed
  47. Blood. 2010 Jul 8;116(1):63-70 - PubMed
  48. Cell. 2010 Jun 25;141(7):1183-94 - PubMed
  49. Mol Cell. 2010 Jun 25;38(6):853-63 - PubMed
  50. Cancer Cell. 2010 Jun 15;17(6):609-21 - PubMed
  51. Nature. 2010 Sep 16;467(7313):343-6 - PubMed
  52. Nat Rev Genet. 2011 Jan;12(1):7-18 - PubMed
  53. J Clin Oncol. 2011 Feb 10;29(5):551-65 - PubMed
  54. J Biol Chem. 2011 Sep 23;286(38):33345-57 - PubMed
  55. Nature. 2011 Aug 03;478(7370):524-8 - PubMed
  56. Nature. 2011 Oct 02;478(7370):529-33 - PubMed
  57. Nat Rev Mol Cell Biol. 2011 Nov 23;12(12):799-814 - PubMed
  58. Blood. 2012 Feb 2;119(5):1151-61 - PubMed
  59. Nature. 2012 Jan 18;481(7381):306-13 - PubMed
  60. Nat Chem Biol. 2012 Jan 29;8(3):277-84 - PubMed
  61. Nature. 2012 Feb 12;482(7386):542-6 - PubMed
  62. Nat Genet. 2012 May 29;44(6):619-22 - PubMed
  63. Nat Rev Mol Cell Biol. 2012 Jun 22;13(7):436-47 - PubMed
  64. Cell. 2012 Jul 6;150(1):12-27 - PubMed
  65. Leukemia. 2013 Jun;27(6):1245-53 - PubMed
  66. Cell Rep. 2013 Jan 31;3(1):116-27 - PubMed
  67. Blood. 2013 Mar 28;121(13):2533-41 - PubMed
  68. Cell. 2013 Feb 28;152(5):1021-36 - PubMed
  69. Mol Cell. 2013 Mar 28;49(6):1108-20 - PubMed
  70. Leukemia. 2013 Nov;27(11):2165-76 - PubMed
  71. N Engl J Med. 2013 May 30;368(22):2059-74 - PubMed
  72. Blood. 2013 Jun 13;121(24):4847-53 - PubMed
  73. Nat Rev Cancer. 2013 Jul;13(7):497-510 - PubMed
  74. Blood. 2013 Aug 8;122(6):1017-25 - PubMed
  75. Genes Chromosomes Cancer. 2013 Oct;52(10):954-60 - PubMed
  76. Blood. 2013 Sep 12;122(11):1914-22 - PubMed
  77. Blood. 2013 Sep 19;122(12):2039-46 - PubMed
  78. Nat Struct Mol Biol. 2013 Oct;20(10):1156-63 - PubMed
  79. Cancers (Basel). 2012 Sep 10;4(3):904-44 - PubMed
  80. Mol Cell. 2014 Jan 23;53(2):247-61 - PubMed
  81. Development. 2014 Feb;141(3):526-37 - PubMed
  82. Leukemia. 2014 Jul;28(7):1427-35 - PubMed
  83. Nucleic Acids Res. 2014 Apr;42(7):4241-56 - PubMed
  84. Leukemia. 2014 Aug;28(8):1586-95 - PubMed
  85. Blood. 2014 Jul 10;124(2):263-72 - PubMed
  86. Cancer Cell. 2014 Apr 14;25(4):530-42 - PubMed
  87. Leukemia. 2015 Jan;29(1):38-50 - PubMed
  88. Cell Rep. 2014 May 22;7(4):1239-47 - PubMed
  89. Mol Cell. 2014 Jul 3;55(1):47-58 - PubMed
  90. Nature. 1995 Nov 30;378(6556):505-8 - PubMed
  91. Cell. 1996 Jun 14;85(6):853-61 - PubMed
  92. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10632-6 - PubMed

Publication Types

Grant support